BR112021004057A2 - métodos de tratar ou prevenir uma infecção micobacteriana, de tratar ou prevenir, de controlar ou reduzir o avanço, severidade ou efeitos de uma doença micobacteriana, tuberculose, lepra, bronquiectasia, doença pulmonar cavitária, linfadenite, uma doença de tecido mole, granuloma de aquário, úlcera de buruli, uma doença ocular e doença óssea em um indivíduo em necessidade dos mesmos, e, métodos de tratar um indivíduo com uma doença pulmonar e de tratar um indivíduo com uma condição imunossuprimida. - Google Patents

métodos de tratar ou prevenir uma infecção micobacteriana, de tratar ou prevenir, de controlar ou reduzir o avanço, severidade ou efeitos de uma doença micobacteriana, tuberculose, lepra, bronquiectasia, doença pulmonar cavitária, linfadenite, uma doença de tecido mole, granuloma de aquário, úlcera de buruli, uma doença ocular e doença óssea em um indivíduo em necessidade dos mesmos, e, métodos de tratar um indivíduo com uma doença pulmonar e de tratar um indivíduo com uma condição imunossuprimida. Download PDF

Info

Publication number
BR112021004057A2
BR112021004057A2 BR112021004057-9A BR112021004057A BR112021004057A2 BR 112021004057 A2 BR112021004057 A2 BR 112021004057A2 BR 112021004057 A BR112021004057 A BR 112021004057A BR 112021004057 A2 BR112021004057 A2 BR 112021004057A2
Authority
BR
Brazil
Prior art keywords
alkyl
alkynyl
alkenyl
individual
alkylsulfinyl
Prior art date
Application number
BR112021004057-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Henry Cynamon
Michael P. Draper
Judith N. Steenbergen
S. Ken Tanaka
Original Assignee
Paratek Pharmaceuticals, Inc.
United States Government As Represented By The Department Of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals, Inc., United States Government As Represented By The Department Of Veterans Affairs filed Critical Paratek Pharmaceuticals, Inc.
Publication of BR112021004057A2 publication Critical patent/BR112021004057A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112021004057-9A 2018-09-04 2019-09-03 métodos de tratar ou prevenir uma infecção micobacteriana, de tratar ou prevenir, de controlar ou reduzir o avanço, severidade ou efeitos de uma doença micobacteriana, tuberculose, lepra, bronquiectasia, doença pulmonar cavitária, linfadenite, uma doença de tecido mole, granuloma de aquário, úlcera de buruli, uma doença ocular e doença óssea em um indivíduo em necessidade dos mesmos, e, métodos de tratar um indivíduo com uma doença pulmonar e de tratar um indivíduo com uma condição imunossuprimida. BR112021004057A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862726738P 2018-09-04 2018-09-04
US62/726,738 2018-09-04
US201862731410P 2018-09-14 2018-09-14
US62/731,410 2018-09-14
US201862746039P 2018-10-16 2018-10-16
US62/746,039 2018-10-16
US201862760131P 2018-11-13 2018-11-13
US62/760,131 2018-11-13
PCT/US2019/049368 WO2020051151A1 (en) 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds

Publications (1)

Publication Number Publication Date
BR112021004057A2 true BR112021004057A2 (pt) 2021-05-25

Family

ID=69722600

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021004057-9A BR112021004057A2 (pt) 2018-09-04 2019-09-03 métodos de tratar ou prevenir uma infecção micobacteriana, de tratar ou prevenir, de controlar ou reduzir o avanço, severidade ou efeitos de uma doença micobacteriana, tuberculose, lepra, bronquiectasia, doença pulmonar cavitária, linfadenite, uma doença de tecido mole, granuloma de aquário, úlcera de buruli, uma doença ocular e doença óssea em um indivíduo em necessidade dos mesmos, e, métodos de tratar um indivíduo com uma doença pulmonar e de tratar um indivíduo com uma condição imunossuprimida.

Country Status (13)

Country Link
US (2) US12161655B2 (https=)
EP (1) EP3846805A4 (https=)
JP (2) JP7466544B2 (https=)
KR (2) KR20260036400A (https=)
CN (1) CN113164456A (https=)
AU (2) AU2019335203B2 (https=)
BR (1) BR112021004057A2 (https=)
CA (1) CA3111447A1 (https=)
MA (1) MA53564A (https=)
MX (2) MX2021002503A (https=)
PH (1) PH12021550452A1 (https=)
SG (1) SG11202102149SA (https=)
WO (1) WO2020051151A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7840880B2 (ja) * 2020-06-11 2026-04-06 パラテック ファーマシューティカルズ,インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
JP2024511419A (ja) * 2021-03-24 2024-03-13 インスメッド インコーポレイテッド 非結核性抗酸菌肺疾患を治療するための併用療法
WO2025221846A1 (en) * 2024-04-18 2025-10-23 St. Jude Children's Research Hospital, Inc. Compositions and methods for treating non-tuberculosis mycobacteria infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009175B1 (ru) 2000-07-07 2007-12-28 Трастис Оф Тафтс Коллидж Замещенные соединения миноциклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния млекопитающего
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2311451A1 (en) 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
TWI680117B (zh) 2008-05-19 2019-12-21 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
KR101732084B1 (ko) 2011-07-26 2017-05-02 케이비피 바이오사이언시즈 씨오., 엘티디. 9-아미노메틸 치환된 테트라사이클린 화합물
JP2015527403A (ja) 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Hivプロテアーゼ阻害剤
CA3018872A1 (en) * 2016-03-24 2017-09-28 Paratek Pharmaceuticals, Inc. Methods of treating a bacterial infection in a subject at risk of developing c. difficile infection
JP2019514952A (ja) * 2016-05-02 2019-06-06 パラテック ファーマシューティカルズ,インコーポレイテッド 9−アミノメチルミノサイクリン化合物及び尿路感染症(uti)の処置におけるその使用方法
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Spv2有限公司 9—胺甲基米諾四環素化合物及其用途
GB201615693D0 (en) * 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations

Also Published As

Publication number Publication date
JP2021536504A (ja) 2021-12-27
US20210346408A1 (en) 2021-11-11
EP3846805A1 (en) 2021-07-14
CN113164456A (zh) 2021-07-23
US20250332178A1 (en) 2025-10-30
US12161655B2 (en) 2024-12-10
MX2021002503A (es) 2021-06-15
AU2025234215A1 (en) 2025-10-16
KR20260036400A (ko) 2026-03-16
AU2019335203B2 (en) 2025-06-19
KR102933150B1 (ko) 2026-03-03
EP3846805A4 (en) 2022-08-24
MA53564A (fr) 2021-07-14
WO2020051151A1 (en) 2020-03-12
SG11202102149SA (en) 2021-04-29
PH12021550452A1 (en) 2021-12-06
MX2024008671A (es) 2024-07-23
JP2024084794A (ja) 2024-06-25
CA3111447A1 (en) 2020-03-12
KR20210090160A (ko) 2021-07-19
AU2019335203A1 (en) 2021-05-06
JP7466544B2 (ja) 2024-04-12

Similar Documents

Publication Publication Date Title
US20250332178A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
Metcalf et al. Use of ethanol locks to prevent recurrent central line sepsis
US11116765B2 (en) Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
JP5469511B2 (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
JP5619352B2 (ja) 細菌を処置するための組成物および方法
EP1077718B1 (en) Enhancement of oxazolidinone antibacterial agents activity by arginine derivatives
CN106456551A (zh) 冻融后形成药物纳米晶体的脂质体
TWI419690B (zh) 使用化合物i來預防或治療生物膜的形成
US20190274978A1 (en) Antibacterial compositions
JP2012501349A (ja) オリタバンシンの単回用量を用いる治療の方法
US20200046653A1 (en) Iron chelator therapy method
US20190307744A1 (en) Pharmaceutical compositions comprising clofazimine analog compound b746 or clofazimine analog compound b826
JP2002500189A5 (https=)
ES2690725T3 (es) Composiciones que comprenden cefepima y tazobactam
US20130338233A1 (en) Methods for microbial biofilm destruction
JP5276653B2 (ja) カルバペネム類を含む殺菌性抗mrsa活性医薬組成物
PT1663233E (pt) Utilização de tigeciclina isolada ou em combinação com rifampina para o tratamento de osteomielite e/ou artrite séptica
RU2831120C2 (ru) Способы лечения микобактериальных инфекций с применением тетрациклиновых соединений
Amangeldykyzy et al. The effect of a combined choline salicylate and cetalkonium chloride gel on particular strains of Pseudomonas aeruginosa, Staphylococcus spp. and Streptococcus spp.
CN114617886A (zh) 化合物及其药学上可接受的盐的抗菌用途
WO2024175768A1 (en) Combination of fabi inhibitor and antibiotic agent
Muggleton Why Cefuroxime?
JP2003525298A (ja) 抗−感染性ectatm
Session I92-MAY 1978 o

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]